Physician profile
Anthony Van Smith
NPI 1740267194
$15,077.31
in general payments reported to CMS, 2019-2025
56 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $1,560 · 2021: $2,896 · 2022: $2,743 · 2023: $2,428 · 2024: $2,215 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,200.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,528.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,567.57 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,511.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $977.94 | 2019-2025 | |
| Lilly USA, LLC | $932.92 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $838.97 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $808.76 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $699.14 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $670.29 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $496.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $382.77 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $380.35 | 2022-2025 | Rexulti |
| Abbott Laboratories | $340.15 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $332.84 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $192.65 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.